PelanserinAlternative Names: TR 2515
Latest Information Update: 30 Aug 2002
At a glance
- Originator Bayer
- Developer Cinvestav
- Class Antihypertensives; Quinazolines; Small molecules; Vasodilators
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Serotonin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hypertension